Augmentation of Exposure Therapy for High Levels of Social Anxiety Using Post-exposure Naps (SANAP)
Social Anxiety Disorder, Sleep Laboratory
About this trial
This is an interventional treatment trial for Social Anxiety Disorder focused on measuring social anxiety, exposure therapy, extinction, sleep-dependent memory consolidation
Eligibility Criteria
Inclusion Criteria:
Inclusion Criteria:
- Treatment-seeking individuals diagnosed with Social Anxiety Disorder using the Structured Clinical Interview for DSM-IV56 (DSM-5 SCID once available)
- A score > 60 on the Liebowitz Social Anxiety Scale (LSAS)13
- 18-40 years of age
- Proficient in English
- Normal or corrected to normal vision
- Able to give informed consent
- Willingness and ability to comply with the requirements of the study protocol
Meets psychophysiological screening criteria for inclusion carried out as follows:
- During a 5-min. baseline period, the candidate participant will sit quietly with skin conductance and orbicularis oculi EMG levels being recorded.
- Toward the end of this period a loud acoustic stimulus will be presented several times and blink startle EMG and SCR will be recorded.
- The candidate subject will then be asked to describe, for 2 min., their most fearful and upsetting past social experience.
- They will then be instructed to silently reimagine this experience as vividly as possible.
- During this imagination period, the loud acoustic stimulus will again be presented several times and blink startle EMG and SCR will be recorded.
- Participants for whom mean SCR and blink startle EMG during the imagining period measurably exceed the means of these measures during baseline will be retained in the study whereas those for whom these measures do not change or are reduced will be excluded.
- This procedure will help ensure that those included in the study will show potentiation of physiological reactivity while anticipating exposure to public speaking.
Exclusion Criteria:
- Any potentially confounding medical illness
- Lifetime history of any neurological illness or injury including neurodegenerative disorders or dementia, stroke, seizure disorders, neurosurgical procedures, head injury resulting in loss of consciousness for greater than 5 min.
- Lifetime history, diagnosed by DSM-IV criteria (or DSM-5 once its SCID available), of bipolar disorder, schizophrenia or other psychotic disorder, pervasive developmental disorder, chronic mental disorder due to a medical condition or other potentially confounding chronic mental disorder.
- Current major depressive, dysthymic or anxiety disorder other than Social Anxiety Disorder or other potentially confounding current mental disorder diagnosed by DSM-IV criteria (or DSM-5 once its SCID available).
- DSM-IV substance abuse or dependence within the last year, lifetime history of hospitalization for substance abuse (determined at clinical interview) or positive urine toxicology screen at the time of the clinical interview
- Any evidence of suicidal ideation, violent behavior or psychosis at the clinical interview
- Use of psychiatric medication within 4 weeks of study (with the exception of 6 weeks for fluoxetine)
- Current psychotherapy for Social Anxiety Disorder
- Any indication of a sleep disorder, particularly sleep-disordered breathing, on the Pittsburgh Structured Clinical Interview for Sleep Disorders
- Sleep onset latency > 1 hr, total sleep time < 5 hr or typical bed time later than 3 AM
- Overnight shift work or recent travel across multiple time zones
- > 4 caffeinated beverages per day or > 11 alcoholic beverages per week
- Nicotine use
Sites / Locations
- Massachusetts General Hospital, One Bowdoin Square
- Massachusetts General Hospital-East, Building 149
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Post-Exposure Nap
Post-Exposure Wake
Sleep-enhancement of extinction memory: At the end of the third and fourth of 5 exposure therapy sessions, all participants deliver a speech designed to elicit significant social anxiety. Following this speech, this arm will be given a 2-hour sleep opportunity with polysomnographic (PSG) monitoring.
At the end of the third and fourth of 5 exposure therapy sessions, all participants deliver a speech designed to elicit significant social anxiety. Following this speech, this arm will be instrumented for PSG but, instead of napping, will undergo 2 hours of quiet wakefulness. Therefore, this arm will not undergo sleep-enhancement of extinction memory.